Brief: Nymox Pharmaceutical announces prostate drug progress

Nymox Pharmaceutical

11/08/2016 15:28

Aug 11 (Reuters) - Nymox Pharmaceutical Corp  NYMX.O : 
    * Says fexapotide has completed 2 long-term large phase 3 
BPH studies in U.S. 
    * Fexapotide will be filed for approval in next 1-2 quarters 
    * Fexapotide will potentially be partnered for marketing 
with larger co if satisfactory terms can be negotiated 
    * Nymox announces prostate drug progress 
    * Says company envisages no significant new cash needs for 
pre-marketing development of fexapotide 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nGNXMZHXQa 
Further company coverage:  NYMX.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))